Open AccessImmunomodulatory drugs in multiple myeloma: Impact of the SCARMET (Self CARe and MEdication Toxicity) educational intervention on outpatients’ knowledge to manage adverse effects
Author(s) -
Juliette Périchou,
Florence Ranchon,
Chloé Herledan,
Laure Huot,
Virginie Larbre,
Isabelle Carpentier,
Anne Lazareth,
Lionel Karlin,
Karen Beny,
Nicolas Vantard,
Vérane Schwiertz,
Anne-Gaëlle Caffin,
Anne Baudouin,
Pierre Sesques,
Gabriel Brisou,
Hervé Ghesquières,
Gilles Salles,
Catherine Rioufol
Publication year - 2020
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0243309
Subject(s) - medicine , pharmacist , adverse effect , clinical endpoint , intervention (counseling) , toxicity , family medicine , pharmacy , emergency medicine , intensive care medicine , nursing , clinical trial
Long-term multiple myeloma therapy by immunomodulatory drugs (IMiDs) raises the question of management of adverse effects. The aim of this study is to assess the impact of an educational session for patients on the acquisition of knowledge to manage hematologic and thromboembolic adverse effects of IMiDs. In this prospective single-center study, patients attended an educational session with a hospital clinical pharmacist and a nurse. The primary endpoint was the patient’s level of knowledge for the management of IMiDs adverse effects, assess with a dedicated questionnaire administered before the session then 1 and 6 months after. Assessment of knowledge was combined with self-assessment of certainty. The secondary endpoints were adherence and IMiD treatment satisfaction. 50 patients were included. Patient knowledge increased at 1 month (p<0.001) despite a loss of knowledge at 6 months (p<0.05). Six months after the educational intervention, the number of patients with skills considered satisfactory by the pharmacist and nurse increased (p<0.01). Most patients showed satisfactory adherence, with medication possession ratio ≥ 80%. The Self CARe and MEdication Toxicity (SCARMET) study highlighted the impact of multidisciplinary follow-up in multiple myeloma patients to improve knowledge of toxicity self-management.